| 标题 |
First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306) |
| 网址 | |
| DOI | |
| 其它 |
期刊:Nature Communications 作者:Harry H. Yoon; Ken Kato; Eric Raymond; Richard Hubner; Yongqian Shu; et al 出版日期:2026-09-03 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人或该文件上传人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)